Committee Backs Novartis’ Coartem; May Be First Drug To Earn Priority Review Voucher
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-infective advisory committee overwhelmingly approves Coartem’s efficacy and safety, but with a laundry list of post-marketing study and labeling recommendations.
You may also be interested in...
Novartis Coartem Review Extends Past Deadline; Priority Review Voucher At Stake
Novartis is optimistic about prospects for near-term FDA approval of malaria drug.
Novartis Coartem Review Extends Past Deadline; Priority Review Voucher At Stake
Novartis is optimistic about prospects for near-term FDA approval of malaria drug.
Priority Review Vouchers: Coartem And The Importance Of Perceptions
The future of the newly enacted priority review voucher incentive program depends heavily on how the first products to qualify for the award are perceived, BIO Ventures for Global Health CEO Christopher Earl told FDC-Windhover's FDA/CMS Summit for Biopharma Executives Dec. 4